PharmaShots CXO Talks: Cytek Biosciences on the Future of Cell Analysis

approach to capturing more biological information through full-spectrum technology, evolving from conventional limitations in flow cytometry to high-parameter systems such as the 60-color Borealis. The conversation also explored how AI, imaging, and cloud-based technologies are being integrated into Cytek's ecosystem to simplify data analysis, accelerate panel design, and make advanced cell analysis easier to use and more accessible.

Reflecting on Cytek's growth and future opportunities, the leaders discussed a customer-first philosophy, the importance of empowering employees and building strong partnerships, and the company's focus on applications including minimal residual disease, cell and gene therapy, and broader research needs. William McCombe also shared how Cytek balances continued investment in technology leadership with sustainable growth and financial discipline.

Can flow cytometry become more powerful, accessible, and easier to use while accelerating the next generation of scientific discovery? According to Dr. Wenbin Jiang, CEO & Chairman of Cytek Biosciences, and William McCombe, CFO of Cytek Biosciences, the answer lies in combining technology leadership with customer-focused innovation, AI-enabled analysis, and strong collaborations.